RNXT | RenovoRx, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9500 - 0.9848
52 Week Range	0.7500 - 1.6900
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	70,521
Average Volume	141,285
Shares Outstanding	36,546,800
Market Cap	35,084,928
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-08-26

Valuation
Profitability
Growth
Health
P/E Ratio	-2.40
Forward P/E Ratio	N/A
EPS	-0.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RNXT's peers: ADIL, APRE, APVO, NTRB, CMMB, COCP, ABVC, EDSA, IKT, INDP, KTTA, KZIA, LGVN, MRKR, NNVC, NRSN, NRXP, AXLA, BTTX, ZIVO, QNRX, ABIO, VRAX, ANEB, SABS, MNPR, ELDN, TPST, IKNA, CBIO, XCUR

*Chart delayed

Analyzing fundamentals for RNXT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see RNXT Fundamentals page.

Watching at RNXT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on RNXT Technicals page.